Vir Biotechnology Inc (NAS:VIR)

$ 11.23 -0.75 (-6.26%) Market Cap: 1.53 Bil Enterprise Value: 499.26 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 55/100

Q1 2024 Vir Biotechnology Inc Earnings Call Transcript
May 02, 2024

$9.18 (+5.03%)

Earnings
Q4 2023 Vir Biotechnology Inc Earnings Call Transcript
Feb 22, 2024

$10.3 (+1.88%)

Earnings
Vir Biotechnology Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Vir Biotechnology Inc AASLD Late Breaking Data Update Call Transcript
Nov 13, 2023
Q3 2023 Vir Biotechnology Inc Earnings Call Transcript
Nov 02, 2023

$8.19 (+5.13%)

Earnings
Vir Biotechnology Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Oct 25, 2023
Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Vir Biotechnology Inc Earnings Call Transcript
Aug 03, 2023

$13.97 (-0.50%)

Earnings
Vir Biotechnology Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Vir Biotechnology Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Vir Biotechnology Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Vir Biotechnology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM Transcript
Jan 10, 2023
Vir Biotechnology Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 18, 2022
Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Vir Biotechnology Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Vir Biotechnology Inc Corporate Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant Transcript
Dec 07, 2021
Vir Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021

Vir Biotechnology Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 05:40PM GMT

Release Date Price: $26.92 (+5.86%)

Transcript

Paul Choi

Goldman Sachs Group, Inc., Research Division - Equity Analyst

Thank you very much. We'll continue with the next session. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's a great pleasure to welcome Vir for this session, and joining us is CEO, Marianne De Backer. We also have Phil Pang, CMO in the audience; and Sung Lee, CFO. What we'll do is some Q&A here and along the way, if you have questions, please e-mail us, and we'll be happy to read your questions anonymously.

Questions & Answers

Paul Choi;Marianne De

Goldman Sachs Group, Inc., Research Division - Equity Analyst

Maybe what we'll start with, Marianne, is maybe some sort of high-level questions. Now that you've been in the CEO role for a little bit now. Can you maybe give us your initial impressions of the company? And what -- how you think about the strengths and weaknesses of the company you've joined here? And then what maybe programs or aspects excite you the most and inspire you to take on this role here?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.